Stimuliver is enrolled into BioInnovation Institute’s Venture Lab program
BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces the first cohort of participants in the Venture Lab acceleration program for early-stage companies. Comprising a pan-European spread of start-up initiatives and university research projects, the seven ventures are developing revolutionary science across BII’s three sector specialised areas – therapeutics, bioindustrials and health tech.
Designed to help build research-based ideas with high-growth commercial potential into viable start-up companies, BII’s 12 month Venture Lab program supports business acceleration, scientific development and team development, and provides a risk-free convertible loan of EUR 500.000 plus access to labs and offices at BII’s entrepreneurial ecosystem in the center of Copenhagen.
Commenting on the launch, Bobby Soni, Chief Business Officer at BioInnovation Institute, said:
“BII’s Venture Lab program offers a platform for bringing ground-breaking science and research ideas to life and will be instrumental in enabling scientists and entrepreneurs to tap into a wealth of expertise and support. We continue to receive many high-quality applications and are delighted to have selected a cohort of first-class initiatives consistent with our ambition to support innovation that will positively impact global health and the environment.”
Giles Dudley, Portfolio Manager at BioInnovation Institute, says the following about Stimuliver:
“Stimuliver is built on world-class research, and we are delighted to work with an international team who are now located here in Copenhagen. What is already clear is that the company isn’t just benefiting from BII support, but also key stakeholders in our local ecosystem who have significant expertise in the cell therapy space. This demonstrates that young companies can benefit in multiple ways when playing an active part in the BII community.”
About Stimuliver
Stimuliver is developing disruptive liver implant technology to treat critically failing liver function in humans. Many people suffer from chronic liver disease. By supporting the liver with our 3D implants, it will help patients sustain critical organ function levels. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. The lab-engineered tissue will be produced from human stem cells, a scalable and renewable clinical resource.,
About BioInnovation Institute
The BioInnovation Institute Foundation (BII) is an international commercial foundation with a non-profit objective supported by the Novo Nordisk Foundation. BII operates an incubator to accelerate world-class life science innovation.
Our vision is to support world-class life science innovation that drives development of new solutions by early life science start-ups for the benefit of people and society.